Patients completing FTY720 Research Evaluating Effects of Daily Oral Therapy in MS ( FREEDOMS ) were eligible for this dose-blinded , parallel-group extension study , continuing fingolimod 0.5 mg/day or 1.25 mg/day , or switching from placebo to either dose , randomized 1:1 .